GPR65 and neoplasm: Total T-cells engineered to express transgenic TCRs from lentiviral vectors specific for the tumour associated epitopes HLA-A2/NY-ESO1157-165 or HLA-A2/MAGE-A4230-239, both expressed by the A375 target cell line, were exposed to GPR65 agonists in killing and cytokine secretion assays.